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ABSTRACT
Introduction: The purpose of this study was to 
evaluate the efficacy of the OptiVis™ Multifocal 
Intraocular Lens (IOL) in patients undergoing 
bilateral crystalline lens replacement following 
extracapsular extraction by phacoemulsification. 
Methods: This was a prospective 6-month, open-
label, nonrandomized clinical trial of subjects 
undergoing bilateral implantation with the 
OptiVis Multifocal IOL. Of the 121 eyes enrolled, 
88 eyes of 44 subjects completed the entire 
6-month trial. Results: After 6 months, the 
majority of eyes had a distance best-corrected 
visual acuity of 20/20 or better, with 89.8% 
achieving that outcome, and 100% with 20/32 
or better. At an intermediate distance, most eyes 
(90.9%) had a distance corrected intermediate 
visual acuity of 20/40 or better, and 53.4% had 
an acuity of 20/32 or better. At a near distance, 
most eyes (95.5%) had a distance corrected near 
visual acuity of 20/40 or better by month 6. The 
most commonly reported adverse event was 
mild-to-moderate halos (n=30, 36%) and mild-to-
moderate glare (n=15, 18%). In addition, there was 
one case of cystoid macular edema, one posterior 
capsular opacification, and one case of severe 
corneal edema. Postoperative contrast sensitivity 
was comparable with normal phakic subjects ≥60 
years of age. Conclusion: The OptiVis Multifocal 
IOL provided satisfactory visual acuity at distance, 
near, and intermediate with no apparent reduction 
in contrast sensitivity. Additional, longer-term 
follow-up studies are planned.
Keywords: bilateral crystalline lens replacement; 
extracapsular extraction; OptiVis Multifocal 
Intraocular Lens; phacoemulsification
INTRODUCTION
A cataract is an opacity or cloudiness of the 
crystalline lens which may prevent a clear 
image from forming in the cornea, and is 
the leading cause of blindness worldwide.1
Age-related cataracts are responsible for 48% of 
world blindness, or about 18 million people.2 In 
the United States, about 300,000-400,000 new 
visually-disabling cataracts occur annually.3
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With the recent introduction of multifocal 
intraocular lenses (IOLs), patients undergoing 
cataract surgery have more treatment options 
than ever before. Multifocal IOLs generate 
different foci in an attempt to overcome the 
visual limitation at near and intermediate 
distances that is associated with conventional 
monofocal IOLs.4 The aim of these multifocal 
IOLs, therefore, is to allow patients to achieve 
spectacle independence. These lenses, however, 
are not without limitations, with some patients 
reporting problems with halos, glare, and loss of 
contrast sensitivity.5,6
The OptiVis™ Multifocal IOL (Aaren Scientific, 
Inc, Ontario, CA, USA) is a relatively new entry 
to the multifocal IOL market and offers several 
advantages over those currently available. The 
lens is distance dominant and has a diffractive 
zone that allows for far and near vision for a 
full range of pupil sizes. The progressive power 
refractive zone allows for far and intermediate 
vision, and the apodized diffractive design is 
intended to minimize light loss outside far and 
near foci in order to reduce halo. Additionally, 
the bi-sign aspherization is designed to improve 
image contrast at large pupils for different 
corneal asphericities, and even with lens tilt 
and/or decentration. The lens is made from 
hydrophilic, acrylic material with UV-absorber, 
and has a refractive index of 1.46. It is a one-
piece design and has earned CE-approval status. 
Specifically, the OptiVis IOL has a posterior 
multifocal surface that consists of three zones: 
central zone (zone 1) is a progressive refractive 
power for far and intermediate distances, within 
central 1.5 mm diameter. The annular zone, 
within 1.5 mm-3.8 mm diameters (zone 2), is the 
apodized diffractive zone for far and 2.5 diopter 
(D) effective (40 cm for near distance) for near. 
The peripheral refractive zone (zone 3) is shaped 
for bi-sign aspherization. The lens drawing in 
Figure 1 demonstrates the three optical zones.
For the OptiVis lens, the zone 1 power profile 
starts at the intermediate power at the center 
of the lens, with the power profile designed to 
extend the focus range from far to intermediate 
distances. The power profile of the negative 
slope of zone 1, and part of the base surface of 
the diffractive zone 2, is intended to expand 
the depth of focus from far to intermediate 
distances. The unique refractive zone of the 
OptiVis lens has the advantage of using 100% of 
the available light sent to the retina for imaging 
which, together with unique apodization of zone 
2, reduce the overall light loss versus any other 
diffractive optic. Ultimately, the design of the 
OptiVis lens allows for a predictable intermediate 
zone lacking in other multifocal lenses, while 
still providing similar vision at far and near.
The purpose of this study was to evaluate the 
efficacy of the OptiVis Multifocal IOL in patients 
undergoing bilateral phacoemulsification. 
METHODS
This study was a 6 month, open-label, 
nonrandomized clinical trial of 121 enrolled 
eyes expected to undergo bilateral implantation 
with the OptiVis multifocal IOL, with the 
second surgery at least 1 week, and no more 
than 4 weeks, after the first surgery. For each 
subject, the decision for which eye to operate 
on first was at the discretion of the physician. 
After each surgery, each subject was examined 
Figure 1. The OptiVis lens.
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7-14 days postoperatively and at 30 days, 
90 days, and 180 days following the second 
surgery. All subjects were treated with the 
normal standard of care for cataract surgery, 
in addition to the specific trial requirements.
Of the 121 eyes enrolled, 108 eyes were 
examined at 1 month, 94 eyes at 3 months, and 
88 eyes of 44 subjects were tested at 6 months.
The mean age of implanted patients was 
70.43 ± 6.33 years with a visual potential of 
20/30 or better in each eye after cataract removal 
and IOL implantation, and a preoperative best 
corrected distance visual acuity (BCDVA) worse 
than Snellen 20/40 (or worse than 20/30 in the 
presence of glare as measured using a Snellen 
chart with Brightness Acuity Tester [BAT] 
at medium). Patients were required to have 
a naturally dilated pupil size (in dim light) 
≥4.0 mm (with no dilation medications) for both 
eyes, a preoperative corneal astigmatism of no 
more than 1.0 D, a clear intraocular media other 
than cataract, and the availability, willingness, 
and sufficient cognitive awareness to comply 
with examination procedures.
Patients were excluded for concurrent 
participation or participation during the last 
30 days in any other clinical trial, or use of 
systemic or ocular medications that may 
affect vision (the use of any miotic agent was 
specifically contraindicated). Patients with 
acute or chronic disease, or illness that would 
increase the operative risk or confound the 
outcome(s) of the study (eg, diabetes mellitus, 
immunocompromized, connective tissue 
disease, etc), were excluded. Subjects with 
diabetes mellitus, or a history of uncontrolled 
systemic or ocular disease (eg, uncontrolled 
ocular hypertension or glaucomatous changes in 
the retina) were also excluded, as were those with 
a history of ocular trauma, prior ocular surgery, 
amblyopia, strabismus, corneal abnormalities 
such as stromal, epithelial, or endothelial 
dystrophies, intraocular inflammation, or 
a recurrent ocular inflammatory condition. 
Moreover, subjects with a known pathology 
that may affect visual acuity, particularly retinal 
changes that affect vision (macular degeneration, 
cystoid macular edema, proliferative diabetic 
retinopathy, etc) were not permitted to enroll, 
nor were patients diagnosed with degenerative 
visual disorders (eg, macular degeneration, or 
other retinal disorders) that were predicted to 
cause future acuity losses to a level of 20/30 or 
worse. Those subjects with pupil abnormalities 
(nonreactive, tonic pupils, abnormally shaped 
pupils, or pupils that do not dilate at least 
4.0 mm under mesopic/scotopic conditions), 
or those presented with a capsule or zonule 
abnormality that may affect postoperative IOL 
centration or tilt; including pseudoexfoliation, 
trauma, or surgical complications (eg, zonular 
rupture, eccentric anterior capsulorhexis) were 
not permitted to enroll. 
Each investigator used a standard small-
incision, phacoemulsification cataract 
extraction surgical technique. Lenses were 
folded for implantation and inserted through 
a suggested 2.5 mm incision size, as per the 
physician’s standard technique when using the 
implantation system. The incisions were either 
clear corneal or scleral tunnel, at the discretion 
of the physician. The anterior capsulotomy 
was a continuous curvilinear capsulorhexis, 
approximately 5.0 mm-5.5 mm in diameter, 
and the lens was to be placed in the capsular bag 
using the recommended insertion device (the 
commercially available Naviject 2.2 1P system 
[Medicel AG, Wolfhalden, Switzerland]). Wound 
closure was left to the surgeon’s discretion, and 
preoperative and intraoperative medications, 
and viscoelastic materials, were used as 
customary for each physician. 
Physicians were to manage the surgical 
outcome to ensure that the total postoperative 
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refractive astigmatism was as minimal 
as possible, with the total postoperative 
astigmatism (including any surgically-induced 
astigmatism) no greater than 1.0 D, regardless 
of axis. Postoperative astigmatism was permitted 
to be managed by incision site placement and 
no additional refractive procedures were to be 
performed during the 6-month postoperative 
study period.
The rights, safety, and wellbeing of the 
participating patients were protected consistent 
with the ethical principles laid down in the 
Declaration of Helsinki. 
Outcome measures included monocular 
uncorrected distance visual acuity (UCDVA) and 
BCDVA under photopic conditions, monocular 
distance corrected intermediate visual acuity 
(at 70 cm) under photopic conditions, and 
monocular distance corrected near visual acuity 
(at 40 cm) under photopic conditions at both 
a fixed distance and the subject’s preferred 
distance. Contrast sensitivity was measured 
in a subset of 28 patients using the Optec®
Functional Visual Analyzer™ (Stereo Optical 
Co., Inc., Chicago, IL, USA).
RESULTS
Eighty-eight eyes of 44 patients completed the 
6-month clinical trials at two clinical sites;
in France and in Italy. 
Demographics
The mean age of implanted patients (121 eyes) 
was 70.43 ± 6.33 years. 
Baseline Acuity
The mean preoperative BCDVA (121 eyes) 
was 20/50 and the mean preoperative UCDVA
(121 eyes) was 20/80. 
Monocular Visual Acuity
BCDVA
The majority of eyes (89.8%) achieved a BCDVA 
of 20/20 or better at month 6, and 100% 
achieved 20/32 or better (Figure 2).
UCDVA
More than half of the eyes (55.7%) achieved 
a UCDVA of 20/20 or better at month 6, and 
96.6% achieved 20/40 or better (Figure 3).
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Distance-Corrected Intermediate Visual 
Acuity (DCIVA)
The majority of eyes (90.9%) had a DCIVA of 
20/40 or better at month 6 (Figure 4), and 34.1% 
had an acuity of 20/25 by month 6.
Uncorrected Intermediate Visual Acuity
Most eyes (78.4%) had an uncorrected 
intermediate visual acuity of 20/40 or better 
at month 6, and 44.3% had an acuity of 20/32 
(Figure 5).
Distance-Corrected Near Visual Acuity
Nearly one third (33.0%) of eyes had a distance-
corrected near visual acuity of 20/25 or better by 
month 6, and 95.5% had an acuity of 20/40 or 
better by month 6 (Figure 6). 
Uncorrected Near Visual Acuity
Most eyes (88.6%) had an uncorrected near 
visual acuity of 20/40 or better by month 6, and 
26.1% had an acuity of 20/25 (Figure 7).
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Contrast Sensitivity
Twenty-eight patients underwent monocular 
contrast sensitivity testing and the results are 
displayed in Figures 8 to 10. 
Monocular Contrast Sensitivity, Daytime 
Conditions (85 cd/m2)
The mean contrast sensitivity of 28 patients 
during daytime conditions, as tested on the 
Functional Visual Analyzer™ (Stereo Optical 
Co., Inc, Chicago, USA) was 1.67 at 1.5 cycles 
per degree (cpd), 1.88 at 3 cpd, 1.79 at 6 cpd, 
1.21 at 12 cpd, and 0.21 at 18 cpd.
Monocular Contrast Sensitivity, Nighttime 
Conditions (3 cd/m2), With No Glare
The mean contrast sensitivity of 28 patients 
during nighttime conditions with no glare, as 
tested on the Functional Visual Analyzer, was 
1.76 at 1.5 cpd, 1.85 at 3 cpd, 1.53 at 6 cpd, 0.60 
at 12 cpd, and 0.20 at 18 cpd.
Monocular Contrast Sensitivity, Nighttime 
Conditions (3 cd/m2), With Glare
The mean contrast sensitivity of 28 patients 
during nighttime conditions with glare, as tested 
on the Functional Visual Analyzer, was 1.60 at 
1.5 cpd, 1.68 at 3 cpd, 1.40 at 6 cpd, 0.54 at 
12 cpd, and 0.14 at 18 cpd.
Patient Satisfaction
Overall, patients were very satisfied with the 
visual outcomes after undergoing implantation 
Figure 8. Monocular contrast sensitivity testing 
(28 patients), Functional Visual Analyzer Test, 
daytime conditions (85 cd/m2).
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Figure 9. Monocular contrast sensitivity testing 
(28 patients), Functional Visual Analyzer Test, 


















Figure 10. Monocular contrast sensitivity testing 
(28 patients), Functional Visual Analyzer Test, 
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with the OptiVis lens. At the month 6 visit,
88.9% of patients reported never wearing 
spectacles and 11.1% reported wearing them only 
sometimes. One-hundred percent of patients 
were either completely (64.6%) or mostly 
(35.4%) satisfied with the postoperative vision 
without glasses during the day. At night, 40.9% 
were completely satisfied with the postoperative 
vision and 50% were mostly satisfied.
Adverse Events
The overall incidence of adverse events was mild-
to-moderate halos at 36% (n=30/84 eyes), with 
22 reported as mild and eight reported as severe. 
Moreover, there was an incidence of 18% of mild-
to-moderate glare (n=15/84 eyes), with only one 
of those patients reporting moderate glare, and 
the remaining 14 reporting only mild glare. In 
addition, there was one case of cystoid macular 
edema, one posterior capsular opacification, and 
one case of severe corneal edema. 
DISCUSSION
The findings of the present study demonstrate 
the efficacy and safety of the OptiVis™ 
multifocal IOL. Patients had satisfactory visual 
outcomes at all distances, with the majority 
of eyes achieving 20/40 or better at distance, 
intermediate, and near. 
The introduction of multifocal IOLs into the 
practice of clinical ophthalmology has enabled 
surgeons to provide patients with an effective 
modality for improving the near and intermediate 
vision, and reducing (or eliminating) dependence 
on spectacles for reading. However, some 
multifocal models have been associated with a 
reduction in visual quality due to glare and halos. 
Those side effects can limit visual function and 
reduce patient quality of life.7 In some models, the 
incidence of glare and halo have been reported to 
range from 6% to 40% for glare, and from 11% 
to 44% for halo.8-11 Although, in recent years, the 
newest multifocal IOLs are typically associated 
with lower incidence of these phenomenon,12-13
a recent study of 2500 patients reported that
6.1% of patients treated with Tecnis™ (Abbott 
Medical Optics Inc., Santa Ana, CA, USA) 
multifocal IOLs experience glare and 2.1% 
experience halo.14 In the present study, the 
incidence of glare and halo was considerably 
lower than many previous reports, with a 
combined incidence of only 6.7%, and no severe 
incidence reported.
Patients in the present study also did not 
appear to have a reduction in contrast sensitivity 
after implantation of the OptiVis Multifocal IOL. 
These results were comparable to a previously 
published report by Hohberger and associates 
who evaluated contrast sensitivity in normal 
subjects in an age cohort similar to the patients 
in this study (>60 years of age).15
The finding that the majority of patients had 
optimal visual outcomes, not only at distance 
and near, but also intermediate, may prove to be 
an advantage of the OptiVis lens relative to other 
multifocal IOL models. Trattler and associates16
recently presented the results of an analysis of 
a patient registry with more than 8000 records 
that suggests that many of these lenses provide 
excellent outcomes at distance, but worse 
outcomes at near and intermediate. For example, 
those authors found that, although mean 
distance acuity was excellent across the lenses 
evaluated, the mean acuities worsened for both 
near and distance. In a recent study by Udaondo 
et al., 126 eyes of 63 patients with bilateral 
cataracts received either OptiVis or ReStor +3™ 
(Alcon Inc., Hunenberg, Switzerland) IOLs 
bilaterally. Although there were no differences 
in neither near, nor intermediate, visual 
acuity, OptiVis patients had significantly better 
intermediate vision, with a preferred working 
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distance of 48.8 cm, compared with a ReStor 
+3.00 preferred working distance of 39.6 cm 
(Data on file, Aaren Scientific).
This OptiVis study has some limitations. It is 
an open-label evaluation of a single product and 
there exists the potential for investigator bias. 
In addition, the study is relatively small and of 
short-term duration. Despite these limitations, 
this trial provides data that demonstrates the 
efficacy and safety of a new multifocal IOL and 
may allow clinicians an additional choice for 
patients undergoing cataract surgery.
CONCLUSION
In conclusion, the OptiVis™ Multifocal IOL 
provided excellent visual acuity at distance, 
near, and intermediate. Additional, longer-term 
follow-up studies are planned.
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